Stock Price
80.63
Daily Change
-1.68 -2.04%
Monthly
-5.98%
Yearly
-8.00%
Q1 Forecast
76.54



Peers Price Chg Day Year Date
Supermax Corporation Bhd 0.29 0.01 1.75% -71.00% Feb/06
Hoya 26,445.00 -495.00 -1.84% 40.37% Feb/06
Ambu A/S 87.90 3.85 4.58% -34.21% Feb/06
Amplifon 13.86 0.08 0.54% -46.90% Feb/06
Apollo Hospitals Enterprise Ltd 7,152.50 30.50 0.43% 5.33% Feb/06
Avanos Medical 14.59 0.74 5.34% -11.63% Feb/06
Brookdale Senior Living 16.12 0.66 4.27% 254.29% Feb/06
Cencora 359.00 6.84 1.94% 44.83% Feb/06
Convatec Group 225.60 -1.60 -0.70% -4.57% Feb/06
Diasorin 73.48 -1.10 -1.47% -26.78% Feb/06

Indexes Price Day Year Date
US500 6932 133.90 1.97% 15.04% Feb/06
US100 25076 527.08 2.15% 16.68% Feb/06

GE HealthCare Technologies traded at $80.63 this Friday February 6th, decreasing $1.68 or 2.04 percent since the previous trading session. Looking back, over the last four weeks, GE HealthCare Technologies lost 5.98 percent. Over the last 12 months, its price fell by 8.00 percent. Looking ahead, we forecast GE HealthCare Technologies to be priced at 76.54 by the end of this quarter and at 69.68 in one year, according to Trading Economics global macro models projections and analysts expectations.

GE HealthCare Technologies Inc. is a medical technology, pharmaceutical diagnostics, and digital solutions company. The Company provides integrated solutions, services, and data analytics. Its segments include Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a comprehensive portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its Ultrasound segment includes ultrasound medical devices and solutions with a portfolio of continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. The segment also includes the clinical artificial intelligence (AI) software business. Its PCS segment portfolio consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment consists of two business lines: contrast media and molecular imaging.